228 results
Page 3 of 12
6-K
EX-99.1
c66u5uxiy6goq3lae2
30 May 23
Current report (foreign)
6:11am
6-K
atfobou5 mwce
17 May 23
Current report (foreign)
6:02am
SD
5juq7lui8f td
15 May 23
Conflict minerals disclosure
6:09am
6-K
32wlhwc1e5ywlu0vyxt
11 May 23
Current report (foreign)
6:10am
6-K
bsjy0zchdhth 2t0x4
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
cdphxb6v
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
f9jci1jkzsoy
21 Dec 22
Current report (foreign)
6:01am
6-K
knhpt
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
u4x57c179jwimg
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
ap75gjnn 9fl
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
woy5ve
30 Nov 22
Current report (foreign)
6:28am
6-K
cdw1 vtieqxv0rivlw
27 Oct 22
Current report (foreign)
6:01am
6-K
EX-99.1
v39logpo mpink1
27 Oct 22
Current report (foreign)
6:01am
6-K
cwtwkehq
14 Oct 22
Current report (foreign)
7:36am
6-K
dtu6y9hb0hz9q1r1 s0b
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
yckqot7247y8vrlx yp5
23 Aug 22
Current report (foreign)
6:13am
6-K
EX-99.1
f6ay7d3
4 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
ehaul2sl12mp 9y
28 Jul 22
Current report (foreign)
6:09am
6-K
6s47r iws
28 Jul 22
Current report (foreign)
6:09am
6-K
7znz 2i20h35iou
11 Jul 22
Current report (foreign)
6:05am